Amgen and Eli Lilly offer treatments for thyroid eye disease, with Lilly's pipeline requiring regulatory approval.
6 reports, 1 independent
Updated Sep 2
Gone quiet
Reached 5 outlets in its first 24 hours
- Reports
- 6
- Developments
- 2
- Repetition
- 83%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Amgen and Eli Lilly offer treatments for thyroid eye disease, with Lilly's pipeline requiring regulatory approval.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- The biotech sector is experiencing a downturn due to drug failures, impacting companies like Amgen and Eli Lilly.Sub-event
Amgen and Lilly are offering treatments for thyroid eye disease.1 source
Keep exploring
The entities involved
-
Amgen
American multinational biopharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Eli Lilly received approval for a plant development in Pennsylvania and paid a milestone payment to Nxera Pharma.
- Eli Lilly and Novo Nordisk products are currently awaiting necessary approval from the Food and Drug Administration.
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.